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Dear Editor,
Response to letter from Dr J. De Vries
and Dr M. Drent. Respir Med Editorial
2000; 94: 187–189fibrosis: which measure should be used? Respir Med
2000; 94: 273–278.
2. Madsen F. Quality of life questionnaires for all
respiratory diseases, every language and ethnic minority,
are alternatives available? Respir Med 2000 94: 187–189.De Vries and Drent address important aspects of the
differences between and the problems with ’quality of life’
(QOL) and ’health-related quality of life’ (HRQOL)
measurement. I agree on the necessity to strengthen focus
on the differences between the disease specific and the
generic instruments.
The letter from De Vries and Drent, especially the
references, makes one happy to learn how far the Dutch
have come in the process of validating disease-specific
questionnaires, especially since this is in a relatively small
language and culture, concerning the size of the population.
What was stressed in the editorial was the fact that we have
developed some very useful generic and disease-specific
instruments, but this has been achieved by fiery souls from
different academies only. The present status is that we have
sucient knowledge to conduct studies with HRQOL and
QOL measurements, and what was stressed in the editorial
was the fact that HRQOL questionnaires have been
developed for a minority of diseases only and only in few
languages and cultures. In my opinion, this is the major
factor limiting the propagation of HRQOL measurements,
and that was why the paper by De Vries et al. (1) was
welcomed. It pointed to alternative methods e.g. the focus
group, in cases where no specific questionnaire exists.
I can fully agree with De Vries and Drent on the necessity
of cultural appropriateness, or in other words, cultural
translation of questionnaires. In fact I found this aspect so
important that it was focused on in the editorial title (2). At
present we do have HRQOL questionnaires for several
diseases, often in the English or American languages. But
we need instruments for the investigation of minorities
concerning language, e.g. Dutch or ethnicity, for examples,
Inuit, and the task to produce these instruments seems
tremendous. That is why alternatives are needed and
proposals are welcome. This also holds for the specifica-
tions we have to demand from our generic questionnaires
and that is why the SF-36 has an advantage, probably being
the one questionnaire validated and translated into most
languages and cultures, thus facilitating transcultural
comparisons of results.
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Dear Editor,
Re: Dose proportionality of fluticosone
proportionate hydrofluoroalkane
pressurized metered dose inhalers
(pMDIS) and comparability with
chlorofluorocarbon pMDIS [Respir Med
2000; 94 (Suppl. B): S10–S16]
I read with interest the recent article by Kunka et al. which
concluded that HFA and CFC formulations of fluticasone
propionate pMDI produced similar lung deposition and no
difference in systemic exposure at microgram equivalent
doses (1). The conclusion of similar lung deposition with
the 125 mg formulation, on the basis of lung bio-
availability, is not supported by the ratio of HFA :CFC
for plasma fluticasone propionate concentration as area
under curve: 0?67 (90% CI 0?57–0?79). For the same 125 mg
formulation, despite the difference in plasma fluticasone
propionate concentration, there appeared to be no differ-
ence in the uncorrected 24-h urinary cortisol excretion,
where the ratio was found to be 1?04 (95% CI 0?82–1?32). It
is conventional practice to report 24-h urinary cortisol
corrected for creatinine excretion. It also seems bizarre that
the investigators have gone to all the trouble of collecting
the serial 24-h plasma fluticasone propionate concentration,
but appear to have omited collecting blood samples over
the same time profile for 24-plasma cortisol, as this would
have permitted proper pharmacokinetic/pharmacodynamic
modelling.
Furthermore, fluticasone propionate was administered as
single doses, and since it has a large volume of distribution,
with preferential partitioning in to the systemic tissue
compartment rather than blood (due to its high lipophili-
city), it would be more clinically relevant to evaluate what
happens with chronic dosing at steady-state, where there
would be a much greater degree of adrenal suppressioin due
to equilibration between the two compartments (2). After-
all, in real life, patients take fluticasone repeatedly twice
daily, not as a single dose. In this situation it is more likely
that differences between the two formulations would
become evident, as suggested by differences between the
pharmacokinetic profiles for the 125 mg formulation in the
study by Kunka.
In this respect, a previous evaluation was made in healthy
volunteers, where steady-state twice daily administration of
HFA and CFC fluticasone propionate (250 mg formula-
tions) were given in doses of 500, 1000 and 2000 mg daily,
